Allergy Therapeutics (AGY) — Capital Reinvestment Ratio
Allergy Therapeutics (AGY) has a Capital Reinvestment Ratio of 0.31x as of December 2021, meaning it reinvests 0% of its operating cash flow (GBX3.71 Million) in capital expenditures (GBX1.15 Million). See Allergy Therapeutics net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Allergy Therapeutics Capital Reinvestment Ratio (2003–2021)
This chart tracks Allergy Therapeutics's Capital Reinvestment Ratio across 11 annual periods. Check Allergy Therapeutics (AGY) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Allergy Therapeutics (2003–2021)
Year-by-year Capital Reinvestment Ratio for Allergy Therapeutics from 2003 to 2021. For live market cap and broader valuation context, see Allergy Therapeutics stock valuation.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.30x | GBX8.52 Million | GBX2.56 Million | ▲ +45.0% |
| 2020 | 0.21x | GBX12.28 Million | GBX2.55 Million | ▼ -58.7% |
| 2019 | 0.50x | GBX5.60 Million | GBX2.81 Million | ▼ -94.0% |
| 2017 | 8.43x | GBX178.00K | GBX1.50 Million | ▲ +2312.2% |
| 2015 | 0.35x | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX2.10 Million | GBX406.00K | — |